COO's Quality Score fell 1 point on Tue, Nov 3, to 5. It closed away from its high of the day (2 chart checks stopped).
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 42% over five years while the S&P 500 rose 74%.
“Operating margin of 21% compared with 17% in last year’s third quarter, driven by lower operating expenses”
−3Long-term trend
| Since its 2024 high | Down 45% |
| Latest filing | 8-K, Oct 27 |
After its last 4 reports it closed -1.2% on average, higher 2 of 4 times.
COO is #39 of 85 by Quality Score.
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 39 |
Net income over four quarters: COO $570M, BLCO -$171M.
Expected to report Thu Dec 10, after the close (in 37 days). Expected.
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“GAAP diluted earnings per share (EPS) of $2.24, compared with $0.49 in last year's third quarter, primarily driven by a $307.2 million discrete tax benefit resulting from the favorable completion of a U.K. tax examination.”
COO's results filing gives no sales by line in a table we read.
| Measure | Figure |
|---|---|
| Total revenue | $1.057B to $1.080B |
“Operating margin of 21% compared with 17% in last year’s third quarter, driven by lower operating expenses, as well as fiscal 2025 inventory and long-lived asset write-offs related to a product line exit at CooperSurgical.”
From its results filing (SEC filing · Sep 9)
Sales grew 11% a year over 5 years, fiscal 2020 to 2025.
Its share count grew 0.2% a year over 5 years.
| Reported | Gap | Reaction | 5 sessions |
|---|---|---|---|
| Sep 9, 2026 | -18.3% | -14.7% | -14.0% |
| Jun 4, 2026 | +5.2% | +8.6% | +8.8% |
| Mar 5, 2026 | -4.0% | -4.5% | -10.8% |
Sales grew in six of the last seven years, to $4.1B in 2025. It made a profit in each of the eight years.
3 insiders bought $1.9M across 5 filings in the last 6 months. No open-market sales on record. The newest:
21 trades disclosed in the last six months. The newest:
Officers and directors with a Form 4 in the last 12 months.
In ETFs: COO is under 0.1% of IVV, under 0.1% of SPY, and under 0.1% of VOO, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026 (SPY's as filed by IVV).
CooperCompanies is one of the largest eyecare companies in the US. It operates in two segments: CooperVision and CooperSurgical. CooperVision is a pure-play contact lens business with a suite of spherical, multifocal, and toric contact lenses. The company also has one of the most comprehensive specialty lens portfolios in the world. With brands including Proclear, Biofinity, MyDay, and Clariti, Cooper controls roughly one fourth of the US contact lens market. CooperSurgical, founded in 1990, is made up of equipment related to reproductive care, fertility, and women's care. Cooper has the broadest medical device coverage of the entire IVF cycle. It also has Paragard, the only hormone-free IUD in the US, and controls 17% of the US IUD market.
“The markets in which we participate are highly competitive and involve the continual search for technological and scientific innovations.”
COO scores 5 today, which Breakaway calls Below Average. It is #39 of 85 in Medical Devices by Quality Score, with 2 of 14 chart checks firing. Down 42% over five years while the S&P 500 rose 74%. Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
COO scores 5 today, which Breakaway calls Below Average (0 to 5). That is #39 of 85 in Medical Devices by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind COO's 5.
3 insiders bought $1.9M across 5 filings in the last 6 months. No open-market sales on record. The newest is Lawrence Erik Kurzius, Director, who bought $549K on Sep 16. Every filing, with the scored weight, for Pro members.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.